Brain Imaging in the Idiopathic REM Sleep Behavior Disorder (ALICE)

3 T Multimodal MRI in Idiopathic RBD

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03072940

Acronym

ALICE

Enrollment

Registered

2017-03-08

Start date

2014-02-28

Completion date

2015-12-31

Last updated

2017-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy, REM Sleep Behavior Disorder

Brief summary

Idiopathic rapid eye movement sleep behavior disorder (iRBD) is characterized by nocturnal violence, increased muscle tone during REM sleep and the lack of any other neurological disease. However, iRBD can precede parkinsonism and dementia by several years. The causes of the loss of muscle atonia during REM sleep in these patients are unclear. Using 3 T MRI and neuromelanin- sensitive sequences, the signal intensity was previously found to be reduce in the locus coeruleus/subcoeruleus area of patients with Parkinson's disease and RBD. Here, the investigators aimed at studying the integrity of the locus coeruleus/ subcoeruleus complex with neuromelanin-sensitive imaging in 21 patients with iRBD and compared the results with those from 21 age- and gender-matched healthy volunteers. All subjects will undergo a clinical examination, motor, cognitive, autonomous, psychological, olfactory and color vision tests, and rapid eye movement sleep characterization using video-polysomnography and 3 T magnetic resonance imaging.

Interventions

OTHERClinical investigations

Clinical examination, motor, cognitive, autonomous, psychological, olfactory and color vision tests, and rapid eye movement sleep characterization using video-polysomnography and 3 T magnetic resonance imaging

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

\- idiopathic RBD (criteria of the international classification of sleep disorders-3) For healthy controls : no neurologic or psychiatric disorder

Exclusion criteria

* Contraindication to MRI * Do not speak French

Design outcomes

Primary

Measure	Time frame	Description
Signal in the subcoeruleus/coeruleus complex	24h	Brain imaging signal in the subcoeruleus/coeruleus complex in 3T multimodal MRI, using neuromelanin-sensitive sequence

Secondary

Measure	Time frame	Description
Substantia nigra quantity	24h	size of the substantia nigra
Quality of Sleep	24h	Measures in videopolysomnography of efficiency of sleep
Cognition	24h	Cognition status (MoCA test)
Olfactory function	24h	Olfactory function (sniff test)
Color vision	24h	Color vision function

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026